US EditionPTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% Following Analyst Downgrade
Summary by americanbankingnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% Following Analyst Downgrade
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price traded down 8.8% during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $78.00 to $75.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. PTC Therapeutics traded as low as $45.40 and last traded […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
